DOI: https://doi.org/10.22263/2312-4156.2019.3.7
Tikhonovskaya I.V., Katina M.A.
Subepidermal bullous dermatoses. Part II. Bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita
Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
Vestnik VGMU. 2019;18(3):7-15.
Abstract.
In the second part of the article dermatoses with subepidermal localization of blisters on histological examination such as bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita are described. The cause of these diseases is unknown. Their autoimmune nature has been proved. Most of them develop in the elderly, so problems in the care of these patients may occur. Clinically and pathomorphologically these dermatoses resemble each other, but the pathogenesis, their course, complications and the associated pathology are different. Diagnosis and differential diagnosis are based on direct immunofluorescence data. Serological studies are one of the methods of diagnosis and are used to monitor the treatment efficacy and the severity of the disease. Immunosuppressive drugs are mainly used for the treatment of this group of diseases that is why a careful monitoring of treatment safety is required. To prevent side effects of immunosuppressive therapy a number of specific tests are necessary.
Key words: bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita.
References
1. Khorvat O, Yankaskova Y, Valker A, Sardi M. Autoimmune diseases of the elderly: pephigoids. Dermatolog. 2015;(3-4):242-8. (In Russ.)
2. Grigor'yev DV. Lever's bullous pemphigoid. RMZh. Dermatologiia. 2014;(8):598-604. (In Russ.)
3. Nevozinskaya ZA, Korsunskaya IM, Denisova EV, Guseva SD, Stoyanova GN, Cherepneva OV, i dr. Lever's bullous pemphigoid in a dermatologist's practice. Consilium Medicum Dermatologiia. 2016;(3):10-1. (In Russ.)
4. Suchkova OM. Bullseed pemphigyodium. Biul Med Internet-konf. 2014;4(5):519. (In Russ.)
5. Hashimoto T, Tsuruta D, Ishii N. Immunoglobulin E Autoantibodies in Bullous Pemphigoid Detected by Immunoglobulin E Enzyme-Linked Immunosorbent Assays. JAMA Dermatol. 2017 Jan;153(1):15-17. doi: http://dx.doi.org/10.1001/jamadermatol.2016.4593
6. van Beek N, Schulze FS, Zillikens D, Schmidt E. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases. Expert Rev Clin Immunol. 2016;12(3):267-77. doi: http://dx.doi.org/10.1586/1744666X.2016.1123092
7. James T, Salman S, Stevenson B, Bundell C, Kelly G, Nolan D, et al. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid. Clin Immunol. 2019 Jan;198:54-56. doi: http://dx.doi.org/10.1016/j.clim.2018.12.015
8. Meijer JM, Diercks GF, Schmidt E, Pas HH, Jonkman MF. Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid. JAMA Dermatol. 2016 Aug;152(8):897-904. doi: http://dx.doi.org/10.1001/jamadermatol.2016.1099
9. Bech R, Kibsgaard L, Vestergaard C. Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature. Fron Med. 2018;5: art 238.
10. Fichel F, Barbe C, Joly P, Bedane C, Vabres P, Truchetet F, et al. Clinical and Immunologic Factors Associated With Bullous Pemphigoid Relapse During the First Year of Treatment A Multicenter, Prospective Study. JAMA Dermatol. 2014 Jan;150(1):25-33. doi: http://dx.doi.org/10.1001/jamadermatol.2013.5757
11. Tikhonovskaya IV, Lesnichaya OV. Localized scarring pemphigoid Brunsting - Perry, clinically reminiscent of lupus erythematosus: a case study. Dermatovenerologiia Kosmetologiia. 2015;(1):95-9. (In Russ.)
12. Adaskevich VP. Dermatoses of pregnant women: metod. rekomendatsii. Minsk, RB: Prof izd; 2018. 69 р. (In Russ.)
13. Kolos YuV, Luk'yanov AM. Bullous dermatoses: diagnostic value of autoantibody detection by enzyme immunoassay. Zdravookhranenie. 2014;(3):56-61. (In Russ.)
14. Makhneva LV, Beletskaya LV. Expression of cadgerine complex adhesion molecules and their role in diagnostics of autoimmune bullous dermatoses. Fundam Issled. 2012;(1):59-63. (In Russ.)
15. Kozlovskaya VV, Beer-Auer A. Dermatoses accompanied by epidermal detachment. Consilium Medicum Dermatologiia. 2014;(4):24-7. (In Russ.)
16. Witte M, Zillikens D, Schmidt E. Diagnosis of Autoimmune Blistering Diseases. Front Med. 2018 Nov;5:296. doi: http://dx.doi.org/10.3389/fmed.2018.00296
17. Bernard F, Antonicelli F. Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment. Am J Clin Dermatol. 2017 Aug;18(4):513-528. doi: http://dx.doi.org/10.1007/s40257-017-0264-2
18. Shetty S, Ahmed AR. Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature. J Drugs Dermatol. 2013 Jun;12(6):672-7.
19. Czernik A, Toosi S, Bystryn JC, Grando SA. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity. 2012 Feb;45(1):111-8. doi: http://dx.doi.org/10.3109/08916934.2011.606452
20. Kremer N, Snast I, Cohen ES, Hodak E, Mimouni D, Lapidoth M, et al. Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature. Am J Clin Dermatol. 2019 Apr;20(2):209-216. doi: http://dx.doi.org/10.1007/s40257-018-0401-6
21. Gupta R, Woodley DT, Chen M. Epidermolysis bullosa acquisita. Clin Dermatol. 2012 Jan-Feb;30(1):60-9. doi: http://dx.doi.org/10.1016/j.clindermatol.2011.03.011
22. Sawicka K, Baraniak J, Michalska-Jakubus M, Przyszlak-Szabała M, Pietrzak A, Mosiewicz J, et al. Mucous membrane pemphigoid as a cause of acute dysphagia – an endoscopic study. Prz Gastroenterol. 2015;10(4):247-9. doi: http://dx.doi.org/10.5114/pg.2015.49475
23. Bruch-Gerharz D, Hertl M, Ruzicka T. Mucous membrane pemphigoid: clinical aspects, immunopathological features and therapy. Eur J Dermatol. 2007 May-Jun;17(3):191-200.
24. Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, et al. The First International Consensus on Mucous Membrane Pemphigoid Definition, Diagnostic Criteria, Pathogenic Factors, Medical Treatment, and Prognostic Indicators. Arch Dermatol. 2002 Mar;138(3):370-9.
25. Kasperkiewicz M, Sadik CD, Bieber K, Ibrahim SM, Manz RA, Schmidt E, et al. Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options. J Invest Dermatol. 2016 Jan;136(1):24-33. doi: http://dx.doi.org/10.1038/JID.2015.356
26. Chikin VV, Znamenskaya LF, Nefedova MA, Charikov VA. Purchased bullous epidermolysis: description of a clinical case. Vestn Dermatologii Venerologii. 2015;(3):109-18. (In Russ.)
27. Vorobyev А, Ludwig RJ, Schmidt E. Clinical features and diagnosis of epidermolysis bullosa acquisita. Expert Rev Clin Immunol. 2017 Feb;13(2):157-169. doi: http://dx.doi.org/10.1080/1744666X.2016.1221343
28. Iwata H, Vorobyev A, Koga H, Recke A, Zillikens D, Prost-Squarcioni C, et al. Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J Rare Dis. 2018 Sep;13(1):153. doi: http://dx.doi.org/10.1186/s13023-018-0896-1
29. Bevans SL, Sami N. The use of rituximab in treatment of epidermolysis bullosa acquisita: Three new cases and a review of the literature. Dermatol Ther. 2018 Nov;31(6):e12726. doi: http://dx.doi.org/10.1111/dth.12726
Information about authors:
Tikhonovskaya I.V. – Candidate of Medical Sciences, associate professor of the Chair of Dermatovenerology, Vitebsk State Order of Peoples’ Friendship Medical University;
Katina M.A. – Candidate of Medical Sciences, associate professor of the Chair of Dermatovenerology, Vitebsk State Order of Peoples’ Friendship Medical University.
Correspondence address: Republic of Belarus, 210009, Vitebsk, 27 Frunze ave., Vitebsk State Order of Peoples’ Friendship Medical University, Chair of Dermatovenerology. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Mariya A. Katina.
